SCHEMBL29438005

SCHEMBL29438005

Cc1noc2cccc(Oc3ccc(NC(=O)[C@@H](C)NC(=O)OC(C)(C)C)cc3)c12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.41
MET P08581 1/20 0.40
JAK2 O60674 2/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
XIAP P98170 1/20 0.38
KIT P10721 3/20 0.38
KDR P35968 3/20 0.38
KDM4E B2RXH2 2/20 0.37
HDAC8 Q9BY41 1/20 0.37
SCN9A Q15858 1/20 0.37
GLA P06280 1/20 0.36
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
FLT3 P36888 1/20 0.36
MMP2 P08253 1/20 0.36
MMP13 P45452 1/20 0.36
SUV39H2 Q9H5I1 1/20 0.36
MMP8 P22894 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9923783 1.00 EPHX2 (0.41) EPHX2METJAK2MEN1KMT2A
SCHEMBL17180631 0.96 XIAP (0.46) EPHX2METJAK2MEN1KMT2A
SCHEMBL9923800 0.88 JAK2 (0.41) JAK2MEN1KMT2AKDM4EGLA
SCHEMBL29437998 0.88 JAK2 (0.41) JAK2MEN1KMT2AKDM4EGLA
SCHEMBL9923785 0.84 KIT (0.39) METMEN1KMT2AKITKDR
SCHEMBL29437992 0.84 KIT (0.39) METMEN1KMT2AKITKDR
SCHEMBL29437973 0.82 XIAP (0.57) METXIAPKITKDRFLT3
SCHEMBL9923801 0.82 XIAP (0.57) METXIAPKITKDRFLT3
SCHEMBL15303500 0.80 MET (0.38) METMEN1KMT2AXIAPKIT
SCHEMBL9924093 0.78 KIT (0.45) METMEN1KMT2AKITKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11583527-B2 Hydantoin derivatives useful as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2023-02-21 US disclosed
US-20220054490-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2022-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11583527-B2 Hydantoin derivatives useful as Kv3 inhibitors KCNN3, KCND3, KCNA3 EPHX2 3045/4885MET 4791/4885JAK2 3204/4885
US-20220054490-A1 HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS KCNN3, KCND3, KCNA3 EPHX2 3045/4885MET 4791/4885JAK2 3204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.